Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Differentiating agent
Arsenic trioxide
Trisenox · ATO
Ancient poison turned APL cure — its differentiation syndrome (plus QT and electrolyte risk) is what threatens the kidneys.
ModerateDifferentiating agent · approved 2000
Acute promyelocytic leukemia (APL)
Signature kidney injury
Prerenal / Hemodynamic AKI
Differentiation syndrome (the main route to AKI) occurs in a substantial minority of APL patients; grade 3–4 renal toxicity in ATO-based regimens is uncommon in randomized data. Direct nephrotoxicity is not well quantified, but QT prolongation and electrolyte disturbances are frequent and clinically important.
Source: Sasijareonrat et al., Technol Cancer Res Treat 2020
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
Incidence not quantified
SeverityModerate
ReversibilityReversible
Evidence0 refs
Nephron map
Vasculature / EndotheliumGlomerular & peritubular capillaries
Proximal Tubule
Distal Tubule / Collecting Duct
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Mechanism of kidney injury
As with ATRA, blast differentiation triggers a cytokine-mediated capillary-leak/differentiation syndrome with hypotension and fluid shifts causing prerenal AKI (and potential ischemic ATN). Arsenic is predominantly renally excreted and prolongs the QT interval; it causes hypokalemia/hypomagnesemia that must be corrected to prevent torsades. Renal impairment reduces arsenic clearance, raising exposure and cardiac/electrolyte risk.
Clinical presentation
Differentiation syndrome (dyspnea, infiltrates, edema, hypotension, acute renal failure); QT prolongation; hypokalemia/hypomagnesemia requiring electrolyte correction. Leukocytosis during induction is common.
Onset
Differentiation syndrome within the first weeks of induction; QT/electrolyte effects throughout treatment.
Reversibility
Reversible
Anticancer mechanism
Arsenic trioxide binds cysteine residues of the PML moiety of the PML-RARA fusion, triggering its SUMOylation and proteasomal degradation; it induces both differentiation (low dose) and apoptosis (high dose) of promyelocytic blasts, curing the majority of APL when combined with ATRA.
Management
Dexamethasone for differentiation syndrome; supportive hemodynamics, aggressive electrolyte repletion and QT monitoring; hold ATO for severe differentiation syndrome or marked QTc prolongation.
Risk factors
- Hyperleukocytosis
- Concurrent QT-prolonging drugs or baseline electrolyte abnormalities
- Bulky disease
- Volume depletion
- Renal impairment (reduced arsenic clearance)
Prevention
- Early/prophylactic corticosteroids for differentiation syndrome
- Maintain potassium >4 mEq/L and magnesium >1.8 mg/dL; serial ECG/QTc monitoring
- Hydration and TLS prophylaxis
- Avoid additive QT-prolonging agents
Note · Renal injury is chiefly a differentiation-syndrome/hemodynamic phenomenon; cardiac (QT) and electrolyte management are integral and become more critical when renal clearance of arsenic falls.
Clinical depth
Renal dose adjustment
No formal CrCl-based dose schedule is established, but because arsenic is largely renally excreted, dose reduction and intensified monitoring are advised in significant renal impairment; the label notes caution and reduced clearance in renal dysfunction. Standard induction is 0.15 mg/kg/day.
Dialyzability & ESKD dosing
Arsenic is partially dialyzable, and case experience supports continuing ATO with dosing around hemodialysis sessions in ESKD; given renal excretion, careful exposure/QT monitoring is essential. This contrasts with most agents in this batch.
Differential diagnosis
Differentiation syndrome (capillary leak, renal failure) vs sepsis vs fluid overload; arsenic-related electrolyte/QT effects vs other QT-prolonging drugs. Separate prerenal/differentiation AKI from tumor lysis by the metabolic profile.
Monitoring
- ECG/QTc at baseline and serially; keep QTc <500 ms
- Potassium and magnesium frequently (replete to high-normal)
- Differentiation-syndrome assessment (weight, oxygenation, symptoms) during induction
- Serum creatinine and tumor-lysis labs
Key trials & series
- Lo-Coco et al., NEJM 2013 — APL0406 (ATRA + arsenic trioxide registrational chemo-free regimen)
- Sasijareonrat et al., Technol Cancer Res Treat 2020 — meta-analysis of differentiation syndrome and renal/cardiac toxicity
Clinical pearls
- Unlike most agents here, arsenic is renally excreted and partly dialyzable — renal impairment raises exposure and QT/electrolyte risk.
- Aggressively keep potassium and magnesium high-normal and watch the QTc to prevent torsades.
- Differentiation syndrome (with renal failure) is the shared ATRA/ATO toxicity — treat early with steroids.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Injury signatures
Prerenal / Hemodynamic AKIAcute Tubular NecrosisElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of differentiating agents.
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Differentiation syndrome
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- QT prolongation
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkRetinoic acid and arsenic trioxide for acute promyelocytic leukemia.Lo-Coco F et al. · N Engl J Med 2013 · PMID 23841729APL0406 registrational trial establishing ATRA + arsenic trioxide as standard; toxicity context.PMIDEfficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies.Sasijareonrat N et al. · Technol Cancer Res Treat 2020 · PMID 32583728Randomized data on differentiation syndrome, renal and cardiac toxicity of arsenic-based APL therapy.PMIDDifferentiation Syndrome in Acute Leukemia: APL and Beyond.Woods AC et al. · Cancers (Basel) 2023 · PMID 37835461Review of differentiation-syndrome pathogenesis and acute renal failure with arsenic/retinoid therapy.PMIDDifferentiation syndrome in acute promyelocytic leukaemia.Stahl M, Tallman MS · Br J Haematol 2019 · PMID 31410848Reviews differentiation syndrome (with acute renal failure) common to ATRA and arsenic trioxide.PMIDHow I treat acute myeloid leukemia with differentiation therapy.Issa GC et al. · Blood 2025 · PMID 38976876Practical management of differentiation syndrome including renal insufficiency, across ATO/ATRA.PMIDDifferentiation Syndrome, a Side Effect From the Therapy of Acute Promyelocytic Leukemia.Reyhanoglu G et al. · Cureus 2020 · PMID 33447473Case of differentiation syndrome (with arsenic) featuring acute renal failure.
Related agents
Other agents sharing the same signature kidney injury.